Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several claims about concomitant vitamin D and monitoring are unsupported or not present in the provided label excerpts; only non-vitamin D-specific atorvastatin metabolism/monitoring statements are partially supported.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is metabolized by CYP3A4 enzymes in the liver.
12.3: “In vitro studies suggest the importance of LIPITOR metabolism by cytochrome P450 3A4...” (CYP3A4 involvement supported; 'in the liver' not explicitly stated in provided excerpt).
Unsupported Statements
Vitamin D does not inhibit or induce the CYP3A4 pathway in any clinically significant way.
No vitamin D-specific statement present in the provided label excerpts.
Most patients experience no change in atorvastatin blood levels when vitamin D is added.
No label evidence provided regarding vitamin D effects on atorvastatin pharmacokinetics.
Doctors verify that the patient's vitamin D blood level is low enough to warrant supplementation.
No label evidence provided for vitamin D testing/supplementation criteria.
Doctors recheck liver enzymes and muscle symptoms after a few weeks if both atorvastatin and vitamin D are used together.
Label supports LFT timing (prior to and at 12 weeks after initiation and after dose increases) and that CPK determinations may be considered in certain situations, but it does not state vitamin D-concomitant timing ('after a few weeks') in the provided excerpts.
Patients who take high-dose vitamin D may need closer monitoring of lipid panels and creatine kinase.
No label evidence provided linking vitamin D dose to enhanced monitoring of lipid panels/CPK.
Patients who already have mild liver impairment may need closer monitoring of lipid panels and creatine kinase.
No label evidence provided for vitamin D-related monitoring adjustments in mild liver impairment (and no label evidence provided about lipid panels/CPK changes based on 'mild liver impairment' in the provided excerpts).
Contradictions
Important Omissions
Warnings/precautions beyond skeletal muscle and liver dysfunction cannot be verified because boxed warnings, contraindications, and other required safety sections are not included in the provided label content.
Importance:
High
Whether/under what conditions vitamin D has any interaction with atorvastatin (or whether such interactions are absent) is not addressed in the provided excerpts; therefore vitamin D-specific assertions cannot be label-confirmed.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Vitamin D-specific claims are unsupported by the provided atorvastatin labeling excerpts; the 'monitoring' guidance tied to vitamin D could mislead about when/how to monitor relative to label-supported atorvastatin monitoring.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple vitamin D + atorvastatin interaction/monitoring claims are absent from the provided FDA label excerpts; only CYP3A4 involvement of atorvastatin metabolism is partially supported.
Suggested Improvement
Remove or rewrite vitamin D-specific CYP3A4/PK/monitoring claims unless supported by provided on-label text; limit statements to label-supported atorvastatin metabolism (CYP3A4 involvement) and atorvastatin monitoring guidance (e.g., LFT timing and CPK considerations) without vitamin D-concomitant timing or dose-threshold assertions.